Skip to main content

Advertisement

SpringerLink
Log in

Opioid rotation in cancer pain

  • Published:
Current Review of Pain Aims and scope Submit manuscript

Abstract

Some patients with cancer pain may develop uncontrolled adverse effects, including generalized myoclonus, delirium, nausea and vomiting, or severe sedation before achieving adequate analgesia during opioid dose titration. When aggressive attempts to provide prophylaxis against adverse effects fail, drug rotation should be considered, because sequential therapeutic trials can identify the most favorable drug. Experiences are accumulating demonstrating that opioid responsiveness to difficult pain syndromes should not be based on the results obtained by a single drug. Different mechanisms, including receptor activity, the asymmetry in cross-tolerance among different opioids, different opioid efficacies, and accumulation of toxic metabolites can explain the differences in analgesic or adverse effect responses among opioids in the clinical setting. Opioid rotation may be useful in opening the therapeutic window and establishing a more advantageous analgesia-toxicity relationship. By substituting opioids and using lower doses it is possible in most cases to reduce or relieve the symptoms of opioid toxicity and to manage highly tolerant patients with previous opioids while improving analgesia and, as a consequence, the opioid responsiveness. Conversion to alternative opioids poses some problems because previous conversion tables may be misleading. Because methadone is much more potent than previously described, any change should start at a lower equivalent dose. Different approaches have been proposed to avoid the problems caused by methadone’s long half-life and possible accumulation. This review will examine the rationale and the clinical aspects of opioid rotation on the basis of recent research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hanks GW, Justins D: Cancer pain: management. Lancet 1992, 339:1031–1036.

    CAS  PubMed  Google Scholar 

  2. Hanks GW, De Conno F, Ripamonti C, et al.: Morphine in cancer pain: modes of administration. Br J Med 1996, 312:826–828. Guidelines produced by a group of experts of the European Association for Palliative Care on the use of morphine in cancer pain.

    Google Scholar 

  3. Crews JC, Sweeney NJ, Denson DD: Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist for management of terminal cancer pain. Cancer 1993, 72:2266–2272.

    CAS  PubMed  Google Scholar 

  4. Morley JS, Watt JWG, Wells JC, et al.: Methadone in pain uncontrolled by morphine. Lancet 1993, 342:1243.

    CAS  PubMed  Google Scholar 

  5. Galer BS, Coyle N, Pasternak GW, et al.: Individual variability in the response to different opioids: report of five cases. Pain 1992, 49:87–91.

    CAS  PubMed  Google Scholar 

  6. Mercadante S: Predictive factors and opioid responsiveness in cancer pain. Eur J Cancer, 1998, 34:627–631.

    CAS  PubMed  Google Scholar 

  7. Pasternak GW, Wood PL: Multiple μ receptors. Life Sci 1986, 38:1889–1898.

    CAS  PubMed  Google Scholar 

  8. Stein C: Peripheral mechanisms of opioid analgesia. Anesth Analg 1993, 76:182–191.

    CAS  PubMed  Google Scholar 

  9. Picard PR, Tramér MR, McQuay HJ, et al.: Analgesic efficacy of peripheral opioids all except intra-articular): a qualitative systematic review of randomised controlled trials. Pain 1997, 72:309–318.

    CAS  PubMed  Google Scholar 

  10. Werz MA, Mac Donald RL: Opiate alkaloids antagonize postsynaptic glycine and GABA responses: correlation with convulsant action. Brain Res 1982, 236:107–119.

    CAS  PubMed  Google Scholar 

  11. Bruera E, MacMillan D, Hanson J, et al.: The Edmonton staging system for cancer pain: preliminary report. Pain 1989, 37:203–210.

    CAS  PubMed  Google Scholar 

  12. Portenoy RK: Tolerance to opioid analgesic: clinical aspects. In Palliative Medicine. Problem Areas in Pain and Symptom Management. Edited by Hanks GW. New York: Cold Spring Harbor Laboratory Press; 1994:49–66.

    Google Scholar 

  13. Desmeules JA, Kayser V, Guilbaud G: Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain. Pain 1993, 53:277–285.

    CAS  PubMed  Google Scholar 

  14. de Stoutz ND, Bruera E, Suarez-Almazor M: Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995, 10:378–384. A clinical study on the effectiveness of opioid rotation in limiting toxicity

    CAS  PubMed  Google Scholar 

  15. Watanabe S, Bruera E: A practical approach to opioid responsiveness in cancer pain. Progr Palliat Care 1994, 2:182–185.

    Google Scholar 

  16. Russell RD and Chang KJ: Alternated delta and mu receptor activation: a stratagem for limiting opioid tolerance. Pain 1989, 36:381–389.

    CAS  PubMed  Google Scholar 

  17. Ivarsson M, Neil A: Differences in efficacies between morphine and methadone demonstrated in guinea pig ileum. Pharmacol Toxicol 1989, 65:368–371.

    CAS  PubMed  Google Scholar 

  18. Mao J, Price D, Mayer DJ: Experimental neuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanism involved in morphine tolerance and neuropathic pain. Pain 1995, 61:353–364. An experimental work on the possible relationships between pain mechanisms and tolerance.

    CAS  PubMed  Google Scholar 

  19. Mogil JS, Stemberg WF, Marek P, et al.: The genetics of pain and pain inhibition. Proc Natl Acad Sci U S A 1996, 93:3048–3055.

    PubMed Central  CAS  PubMed  Google Scholar 

  20. Mogil JS, Kest B, Sadowski B, et al.: Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: influence of nociceptive assay. J Pharmacol Exp Ther 1996, 276:532–544.

    CAS  PubMed  Google Scholar 

  21. Neil A: Morphine and methadone tolerant mice differ in crosstolerance to other opiates. Arch Pharmacol 1982, 320:50–53.

    CAS  Google Scholar 

  22. Pick CG, Cheng J, Paul D, et al.: Genetic influences in opioid analgesic sensitivity in mice. Brain Res 1991, 566:295–298.

    CAS  PubMed  Google Scholar 

  23. Portenoy RK, Foley KM, Inturrisi CE: The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990, 43:273–286.

    CAS  PubMed  Google Scholar 

  24. Duttaroy A, Yoburn BC: The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 1995, 82:1226–1236.

    CAS  PubMed  Google Scholar 

  25. Sosnowski M, Yaksh TL: Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anesthesiology 1990, 73:1141–1147.

    CAS  PubMed  Google Scholar 

  26. Dirig DM, Yaksh TL: Differential right shifts in the doseresponse curve for intrathecal morphine and sufentanil as a function of stimulus intensity. Pain 1995, 62:321–328.

    CAS  PubMed  Google Scholar 

  27. Kissin I, Brown P, Bradley E: Magnitude of acute tolerance to opioids is not related to their potency. Anesthesiology 1991, 75:813–816.

    CAS  PubMed  Google Scholar 

  28. Frenk H, Watkins LR, Mayer DJ: Differential behavioral effects induced by intrathecal microinjection of opiates: comparison of convulsive and cataleptic effects produced by morphine, methadone, and D-ala-methionine-enkephalinamide. Brain Res 1984, 299:31–42.

    CAS  PubMed  Google Scholar 

  29. Saeki S, Yaksh TL: Suppression of nociceptive responses by spinal mu opioid agonists: effects of stimulus intensity and agonist efficacy. Anesth Analg 1993, 77:265–274.

    CAS  PubMed  Google Scholar 

  30. Andersen S, Dickenson AH, Kohn M, et al.: The opioid ketobemidone has a NMDA blocking effect. Pain 1996, 67:369–374.

    CAS  PubMed  Google Scholar 

  31. Ebert B, Andersen S, Krogsgaard-Larsen P: Ketobemidone, methadone and pethidine are non-competitive N-methyl-Daspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995, 187:165–168.

    CAS  PubMed  Google Scholar 

  32. Mercadante S: Methadone in cancer pain. Eur J Pain 1997, 1:77–85.

    CAS  PubMed  Google Scholar 

  33. Faura CC, Olaso MJ, Cabanes CG, et al.: Lack of morphine-6- glucuronide antinociception after morphine treatment. Is morphine- 3-glucuronide involved? Pain 1996, 65:25–30.

    CAS  PubMed  Google Scholar 

  34. France B, Gout R, Monsarrat B, et al.: Further evidence that morphine-6-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther 1992, 262:25–31.

    Google Scholar 

  35. Gong QL, Hedner J, Bjorkman R, et al.: Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression. Pain 1992, 48:249–255.

    CAS  PubMed  Google Scholar 

  36. Smith MT, Watt JA, Crammond T: Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci 1990, 47:579–585.

    CAS  PubMed  Google Scholar 

  37. Osborne R, Joel S, Trew D, et al.: Morphine and morphine metabolite behaviour after different routes of administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Clin Biochem 1990, 47:12–19.

    CAS  Google Scholar 

  38. Peterson GM, Randall CTC, Paterson J: Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 1990, 38:121–124.

    CAS  PubMed  Google Scholar 

  39. Sawe J: High-dose morphine and methadone in cancer patients: clinical considerations of oral treatment. Clin Pharmacokin 1986, 11:87–106.

    CAS  Google Scholar 

  40. D’Honneur G, Gilton A, Sandouk P, et al.: Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine: the influence of renal failure. Anesthesiology 1994, 81:87–93.

    PubMed  Google Scholar 

  41. Osborne RJ, Joel SP, Slevin ML: Morphine intoxication in renal failure: the role of morphine-6-glucuronide. BMJ 1986, 292:1548–1549.

    PubMed Central  CAS  PubMed  Google Scholar 

  42. Portenoy RK, Foley KM, Stulman J, et al.: Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991, 47:13–19.

    CAS  PubMed  Google Scholar 

  43. Calleja MA, Childs D, Venn RF, et al.: Persistently increased morphine-6-glucuronide concentrations. Br J Anaesth 1990, 64:649.

    CAS  PubMed  Google Scholar 

  44. Bowsher D: Paradoxical pain. BMJ 1993, 306:473.

    PubMed Central  CAS  PubMed  Google Scholar 

  45. Goucke CR, Hackett LP, Ilett KF: Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain. Pain 1994, 56:145–149.

    CAS  PubMed  Google Scholar 

  46. Woolf T, Samuelsson H, Hedner T: Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain 1995, 62:147–154.

    Google Scholar 

  47. Sjölgren P, Jonsson T, Jensen NH, et al.: Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993, 55:93–97.

    Google Scholar 

  48. Zaw-Tun N, Bruera E: Active metabolites of morphine. J Palliat Care 1992, 8:48–50.

    CAS  PubMed  Google Scholar 

  49. Hagen NA, Foley KM, Cerbone DJ, et al.: Chronic nausea and morphine- 6-glucuronide. J Pain Symptom Manage 1991, 6:125–128.

    CAS  PubMed  Google Scholar 

  50. Thomas Z, Bruera E: Use of methadone in a highly tolerant patient receiving parenteral hydromorphone. J Pain Symptom Manage 1995, 10:315–317.

    CAS  PubMed  Google Scholar 

  51. Sjögren P, Dragsted L, Christensen CB: Myoclonic spasm during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 1993, 37:780–782.

    PubMed  Google Scholar 

  52. Sjögren P, Jensen NH, Jensen TS: Disappearance of morphineinduced hyperalgesia after discontinuing or substituting with other opioid agonists. Pain 1994, 59:313–316.

    PubMed  Google Scholar 

  53. Tiseo PJ, Thaler HT, Lapin J, et al.: Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995, 61:47–54.

    CAS  PubMed  Google Scholar 

  54. Glare PA, Walsh TD, Pippenger CE: Normorphine, a neurotoxic metabolite? Lancet 1990, 335:725–728.

    CAS  PubMed  Google Scholar 

  55. Kaiko RK, Foley K, Grabinski PY, et al.: Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983, 13:150–185.

    Google Scholar 

  56. Babul N, Darke AC: Putative role of hydromorphone metabolites in myoclonus. Pain 1992, 51:260–261.

    CAS  PubMed  Google Scholar 

  57. Eisele JH, Grisby EJ, Dea G: Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 1992, 49:213–232.

    Google Scholar 

  58. Gannon C: The use of methadone in the care of the dying. Eur J Palliat Care 1997, 4:152–158.

    Google Scholar 

  59. Hanks GW, Forbes K: Opioid responsiveness. Acta Anaesthesiol Scand 1997, 41:154–158.

    CAS  PubMed  Google Scholar 

  60. Fallon M: Opioid rotation: does it have a role? Palliat Med 1997, 11:177–178.

    CAS  PubMed  Google Scholar 

  61. Cherny NJ, Chang V, Frager G, et al.: Opioid pharmacotherapy in the management of cancer pain. Cancer 1995, 76:1288–1293.

    Google Scholar 

  62. Schug SA, Zech D, Grond S, et al.: A long term survey of morphine in cancer pain patients. J Pain Symptom Manage 1992, 7:259–266.

    CAS  PubMed  Google Scholar 

  63. Fitzgibbon DR, Ready LB: Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion in the treatment of cancer pain refractory to highdose morphine. Pain 1997, 73:259–261.

    CAS  PubMed  Google Scholar 

  64. Bruera E, Brenneis C, Michaud M, et al.: Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 1988, 62:407–411.

    CAS  PubMed  Google Scholar 

  65. Drexel H, Dzien A, Spiegel RW, et al.: Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain 1989, 36:169–176.

    CAS  PubMed  Google Scholar 

  66. Kalso E, Heiskanen T, Rantio M, et al.: Epidural and subcutaneous morphine in the management of cancer pain: a double blind cross-over study. Pain 1996, 67:443–449. The first randomized, double-blind and cross-over study comparing the effectiveness and acceptability of epidural and subcutaneous administration of morphine in cancer pain management.

    CAS  PubMed  Google Scholar 

  67. Hogan Q, Haddox JD, Abram S, et al.: Epidural opiates and local anesthetics for the management of cancer pain. Pain 1991, 46:271–279.

    CAS  PubMed  Google Scholar 

  68. Bruera E, Macmillian K, Selmser P, et al.: Decreased local toxicity with subcutaneous diamorphine (heroin): a preliminary report. Pain 1990, 43:91–94.

    CAS  PubMed  Google Scholar 

  69. Bruera E, Fainsinger R, Moore M, et al.: Clinical note: local toxicity with subcutaneous methadone- experience of two centers. Pain 1991, 45:141–143.

    CAS  PubMed  Google Scholar 

  70. Bruera E, Pereira J, Watanabe S, et al.: Opioid rotation in patients with cancer pain: a retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996, 78:852–857. One of the first studies that determined the equianalgesic dose ratios between the principal opioids used in cancer pain, showing a positive correlation between dose ratio and previous dose of hydromorphone and morphine when rotating to methadone.

    CAS  PubMed  Google Scholar 

  71. Ripamonti C, Zecca E, Brunelli C, et al.: Rectal methadone in cancer patients with pain: a preliminary clinical and pharmacokinetic study. Ann Oncol 1995, 6:841–843.

    CAS  PubMed  Google Scholar 

  72. Warren DE: Practical use of rectal medications in palliative care. J Pain Symptom Manage 1996, 11:378–387.

    CAS  PubMed  Google Scholar 

  73. Weinberg DS, Inturrisi CE, Reidenberg, et al.: Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988, 44:335–342.

    CAS  PubMed  Google Scholar 

  74. Ahmezdai S, Brooks D: Transdermal fentanyl versus sustainedrelease oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 1997, 13:254–261.

    Google Scholar 

  75. Donner B, Zenz M, Tryba M, et al.: Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996, 64:527–534.

    CAS  PubMed  Google Scholar 

  76. Janssen Pharmaceutica Inc: “Duragesic”, fentanyl transdermal system, product monograph. Mississauga, Ontario; 1991.

  77. MacDonald N: Letter. J Pain Symptom Manage 1993, 8:320–321.

    Google Scholar 

  78. Fine PG, Marcus M, De Boer AJ, et al.: An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991, 45:149–153.

    CAS  PubMed  Google Scholar 

  79. Patt R: Letter. J Pain Symptom Manage 1993, 8:322–323.

    Google Scholar 

  80. Korte W and Morant R: Transdermal fentanyl in uncontrolled cancer pain: titration on day-to-day basis as a procedure for safe and effective dose finding: a pilot study in 20 patients. Support Care Cancer 1994, 2:123–127.

    CAS  PubMed  Google Scholar 

  81. Davies AN, Bond C: Transdermal fentanyl and the opioid withdrawal syndrome. Palliat Med 1996, 10:348.

    CAS  PubMed  Google Scholar 

  82. Hunt R: Transdermal fentanyl and the opioid withdrawal syndrome. Palliat Med 1996, 10:347–348.

    CAS  PubMed  Google Scholar 

  83. Higgs CMB, Vella Brincat J: Withdrawal with transdermal fentanyl. J Pain Symptom Manage 1995, 10:4–5.

    CAS  PubMed  Google Scholar 

  84. Zech DFJ, Grond S, Lynch J, et al.: Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain: a pilot study with 20 terminally ill cancer patients. Pain 1992, 50:293:301.

    Google Scholar 

  85. Sjögren P, Banning A: Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain 1989, 39:5–11.

    PubMed  Google Scholar 

  86. Vainio A, Tigerstedt I: Opioid treatment for radiation cancer pain: oral vs. epidural techniques. Acta Anesthesiol Scand 1988, 32:179–185.

    CAS  Google Scholar 

  87. Plummer JL, Cherry DA, Cousins MJ, et al.: Long-term spinal administration of morphine in cancer and non-cancer pain: a retrospective study. Pain 1991, 44:215–220.

    CAS  PubMed  Google Scholar 

  88. Parkinson SK, Bailey SL, Little WL, et al.: Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiology 1990, 72:743–745.

    CAS  PubMed  Google Scholar 

  89. De Conno F, Caraceni A, Martini C, et al.: Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991, 47:337–339.

    CAS  PubMed  Google Scholar 

  90. Samuelsson H, Malberg F, Eriksson M, et al.: Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage 1995, 10:105–112.

    CAS  PubMed  Google Scholar 

  91. de Leon Casasola, Lema MJ: Epidural bupivacaine/sufentanil therapy for postoperative pain control in patients tolerant to opioids and unresponsive to epidural bupivacaine/morphine. Anesthesiology 1994, 80:303–309.

    Google Scholar 

  92. Manfredi PL, Chandler SW, Patt R, et al.: High-dose epidural infusion of opioids for cancer pain: cost issues. J Pain Symptom Manage 1997, 13:118–121.

    CAS  PubMed  Google Scholar 

  93. Fainsinger R, Bruera E: The management of dehydration in terminally ill patients. J Palliat Care 1994, 10:55–59.

    CAS  PubMed  Google Scholar 

  94. Kirkham SR, Pugh R: Opioid analgesia in uraemic patients. Lancet 1995, 345:1185.

    CAS  PubMed  Google Scholar 

  95. Paix A, Coleman A, Lees J, et al.: Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 1995, 61:263–269.

    Google Scholar 

  96. Ripamonti C, Zecca E, Bruera E: An update on the clinical use of methadone for cancer pain. Pain 1997, 70:109–115. The most recent review on the clinical use of methadone in cancer pain.

    CAS  PubMed  Google Scholar 

  97. Singer M, Noonan KR: Continuous intravenous infusion of fentanyl: case reports of use in patients with advanced cancer and intractable pain. J Pain Symptom Manage 1993, 8:215–220.

    CAS  PubMed  Google Scholar 

  98. Kreek MJ, Schecter AJ, Gutjahr CL, et al.: Methadone use in patients with chronic renal disease. Drug Alcohol Depend 1980, 5:197–205.

    CAS  PubMed  Google Scholar 

  99. Bruera E, Schoeller T, Fainsinger RL, et al.: Custom-made suppositories of methadone for severe cancer pain. J Pain Symptom Manage 1992, 7:372–374.

    CAS  PubMed  Google Scholar 

  100. Bruera E, Watanabe S, Fainsinger RL, et al.: Custom-made capsules and suppositories of methadone for patients on high dose opioids for cancer pain. Pain 1995, 62:141–146.

    CAS  PubMed  Google Scholar 

  101. Portnow JM, Corbett RJ: Oral methadone for relief of chronic pain from cancer. N Engl J Med 1982, 306:889–990.

    Google Scholar 

  102. Leng G, Finnegan MJ: Successful use of methadone in nociceptive cancer pain unresponsive to morphine. Palliat Med 1994, 8:153–155.

    CAS  PubMed  Google Scholar 

  103. MacDonald N, Der L, Allen S, Champion F: Opioid hyperexcitability: the application of an alternate opioid therapy. Pain 1993, 53:353–355.

    CAS  PubMed  Google Scholar 

  104. Rimmer T, Trotman I: Methadone restores opioid sensitivity in cancer pain. Palliat Med 1996, 10:58.

    Google Scholar 

  105. Manfredi PL, Borsook D, Chandler SW, et al.: Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observation. Pain 1997, 70:99–101.

    CAS  PubMed  Google Scholar 

  106. Viganò A, Fan D, Bruera E: Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 1996, 67:115–119.

    PubMed  Google Scholar 

  107. Bruera E, MacMillian K, Hansen J: The cognitive effect of the administration of narcotic analgesics in patients with cancer pain. Pain 1989, 39:13–16.

    CAS  PubMed  Google Scholar 

  108. Bruera E: Severe organic brain syndrome. J Palliat Care 1991, 7:36–38.

    CAS  PubMed  Google Scholar 

  109. Bruera E, Schoeller T, Montejo G: Organic hallucinosis in patients receiving high doses of opiates for cancer pain. Pain 1992, 48:397–399.

    CAS  PubMed  Google Scholar 

  110. Maddocks I, Somogyi A, Abbott F, et al.: Attenuation of morphine- induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 1996, 12:182–189. A clinical experience on the reduction of neurotoxic symptoms after switching from morphine to oxycodone.

    CAS  PubMed  Google Scholar 

  111. Mercadante S, Caligara M, Sapio M, et al.: Subcutaneous fentanyl infusion in obstructed patient with renal failure. J Pain Symptom Manage 1997, 13:241–244.

    CAS  PubMed  Google Scholar 

  112. Hunt G, Bruera E: Respiratory depression in a patient receiving oral methadone for cancer pain. J Pain Symptom Manage 1995, 10:401–404.

    CAS  PubMed  Google Scholar 

  113. Lawlor P, Turner K, Hanson J, Bruera E: Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 1998, 82:1167–1173. This study determines the equianalgesic dose ratio between morphine and methadone. The dose ratio changes as a function of previous opioid dose. The results highlight the general underestimation of methadone potency, based on previous equianalgesic references tables and the consequent risk of potential life-threatening toxicity.

    CAS  PubMed  Google Scholar 

  114. Lawlor P, Turner K, Hanson J, et al.: Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997, 72:79–85. Equianalgesic dose ratio between morphine and hydromorphone. The opioid to which the patient is rotated is relatively more potent. No relationship between previous opioid dose and dose ratio for rotations has been found.

    CAS  PubMed  Google Scholar 

  115. Morley JS, Makin MK: Comments on Ripamonti et al. Pain 1997, 73:14.

    Google Scholar 

  116. Mercadante S, Sapio M, Serretta R, et al.: Patient-controlled analgesia with oral methadone in cancer patients: preliminary report. Ann Oncol 1996, 7:613–618. Patient-administered analgesia with oral methadone appears to be a simple and relatively safe technique to permit individualization of therapy and to avoid the risk of accumulation.

    CAS  PubMed  Google Scholar 

  117. Fitzgibbon DR, Ready B: Intravenous high dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high dose morphine. Pain 1997, 73:259–261.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pain Relief and Palliative Care, SAMOT, via Libertà 191, 90143, Palermo, Italy

    Sebastiano Mercadante MD (Medical Director)

Authors
  1. Sebastiano Mercadante MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mercadante, S. Opioid rotation in cancer pain. Current Review of Pain 2, 131–142 (1998). https://doi.org/10.1007/s11916-998-0010-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-998-0010-9

Keywords

Search

Navigation